scholarly journals Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury

Gut ◽  
2019 ◽  
Vol 69 (1) ◽  
pp. 133-145 ◽  
Author(s):  
Yuan Zhuang ◽  
Haifeng C Xu ◽  
Prashant V Shinde ◽  
Jens Warfsmann ◽  
Jelena Vasilevska ◽  
...  

ObjectiveThe Fragile X mental retardation (FMR) syndrome is a frequently inherited intellectual disability caused by decreased or absent expression of the FMR protein (FMRP). Lack of FMRP is associated with neuronal degradation and cognitive dysfunction but its role outside the central nervous system is insufficiently studied. Here, we identify a role of FMRP in liver disease.DesignMice lacking Fmr1 gene expression were used to study the role of FMRP during tumour necrosis factor (TNF)-induced liver damage in disease model systems. Liver damage and mechanistic studies were performed using real-time PCR, Western Blot, staining of tissue sections and clinical chemistry.ResultsFmr1null mice exhibited increased liver damage during virus-mediated hepatitis following infection with the lymphocytic choriomeningitis virus. Exposure to TNF resulted in severe liver damage due to increased hepatocyte cell death. Consistently, we found increased caspase-8 and caspase-3 activation following TNF stimulation. Furthermore, we demonstrate FMRP to be critically important for regulating key molecules in TNF receptor 1 (TNFR1)-dependent apoptosis and necroptosis including CYLD, c-FLIPS and JNK, which contribute to prolonged RIPK1 expression. Accordingly, the RIPK1 inhibitor Necrostatin-1s could reduce liver cell death and alleviate liver damage in Fmr1null mice following TNF exposure. Consistently, FMRP-deficient mice developed increased pathology during acute cholestasis following bile duct ligation, which coincided with increased hepatic expression of RIPK1, RIPK3 and phosphorylation of MLKL.ConclusionsWe show that FMRP plays a central role in the inhibition of TNF-mediated cell death during infection and liver disease.

2019 ◽  
Author(s):  
Jean-Philippe Parvy ◽  
Yachuan Yu ◽  
Anna Dostalova ◽  
Shu Kondo ◽  
Alina Kurjan ◽  
...  

AbstractAntimicrobial peptides (AMPs) are small cationic molecules best known as mediators of the innate defence against microbial infection. While in vitro and ex vivo evidence suggest AMPs’ capacity to kill cancer cells, in vivo demonstration of an anti-tumour role of endogenous AMPs is lacking. Using a Drosophila model of tumourigenesis, we demonstrate a role for the AMP Defensin in the control of tumour progression. Our results reveal that Tumour Necrosis Factor mediates exposure of phosphatidylserine (PS), which makes tumour cells selectively sensitive to the action of Defensin remotely secreted from tracheal and fat tissues. Defensin binds tumour cells in PS-enriched areas, provoking cell death and tumour regression. Altogether, our results provide the first in vivo demonstration for a role of an endogenous AMP as an anti-cancer agent, as well as a mechanism that explains tumour cell sensitivity to the action of AMPs.


2013 ◽  
Vol 144 (5) ◽  
pp. S-447
Author(s):  
Babu Vadamalayan ◽  
Dinesh Banur ◽  
Marianne Samyn ◽  
Giorgina Mieli-Vergani ◽  
Nedim Hadzic

eLife ◽  
2019 ◽  
Vol 8 ◽  
Author(s):  
Jean-Philippe Parvy ◽  
Yachuan Yu ◽  
Anna Dostalova ◽  
Shu Kondo ◽  
Alina Kurjan ◽  
...  

Antimicrobial peptides (AMPs) are small cationic molecules best known as mediators of the innate defence against microbial infection. While in vitro and ex vivo evidence suggest AMPs’ capacity to kill cancer cells, in vivo demonstration of an anti-tumour role of endogenous AMPs is lacking. Using a Drosophila model of tumourigenesis, we demonstrate a role for the AMP Defensin in the control of tumour progression. Our results reveal that Tumour Necrosis Factor mediates exposure of phosphatidylserine (PS), which makes tumour cells selectively sensitive to the action of Defensin remotely secreted from tracheal and fat tissues. Defensin binds tumour cells in PS-enriched areas, provoking cell death and tumour regression. Altogether, our results provide the first in vivo demonstration for a role of an endogenous AMP as an anti-cancer agent, as well as a mechanism that explains tumour cell sensitivity to the action of AMPs.


Immunology ◽  
2008 ◽  
Vol 125 (4) ◽  
pp. 522-534 ◽  
Author(s):  
Nasiema Allie ◽  
Lena Alexopoulou ◽  
Valerie J. F. Quesniaux ◽  
Lizette Fick ◽  
Ksanthi Kranidioti ◽  
...  

1985 ◽  
Vol 22 (3) ◽  
pp. 291-294 ◽  
Author(s):  
D.K.K. Ha ◽  
S.W. Leung ◽  
K.P. Fung ◽  
Y.M. Choy ◽  
C.Y. Lee

2009 ◽  
Vol 36 (2) ◽  
pp. 100-105 ◽  
Author(s):  
Tuomas Saxlin ◽  
Liisa Suominen-Taipale ◽  
Jaana Leiviskä ◽  
Antti Jula ◽  
Matti Knuuttila ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document